Zhigang Lu

Prof. Zhigang Lu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
JJJian-Jian Ji
Jian-Jian Ji
QSQin-Mei Sun
Qin-Mei Sun
DNDeng-Yun Nie
Deng-Yun Nie
QWQian Wang
Qian Wang
HZHan Zhang
Han Zhang
ZLZhigang Lu
Zhigang Lu

1 January 2019 in Life Sciences
Verified
Journal Article
Closed access
HZHan Zhang
Han Zhang
FQFenfen Qin
Fenfen Qin
ALAnlong Liu
Anlong Liu
QSQinmei Sun
Qinmei Sun
QWQisheng Wang
Qisheng Wang
ZLZhigang Lu
Zhigang Lu

20 March 2020 in Inflammation
Verified
Journal Article
Closed access
PDF file
MYMei-Ling Yu
Mei-Ling Yu
RWRui-De Wei
Rui-De Wei
TZTao Zhang
Tao Zhang
JWJun-Meng Wang
Jun-Meng Wang
YCYu Cheng
Yu Cheng
SLShengfeng Lu
Shengfeng Lu

20 January 2023 in Biochemical Pharmacology
Verified
Journal Article
Closed access
QSQinmei Sun
Qinmei Sun
ZLZhonghao Li
Zhonghao Li
ZWZijing Wang
Zijing Wang
QWQisheng Wang
Qisheng Wang
FQFenfen Qin
Fenfen Qin
ZLZhigang Lu
Zhigang Lu

25 September 2022 in Phytomedicine
Verified
Journal Article
Closed access
ZLZhonghao Li
Zhonghao Li
QSQinmei Sun
Qinmei Sun
QLQingyang Liu
Qingyang Liu
XMXinru Mu
Xinru Mu
HWHui Wang
Hui Wang
ZLZhigang Lu
Zhigang Lu

24 April 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FQFenfen Qin
Fenfen Qin
HZHan Zhang
Han Zhang
ALAnlong Liu
Anlong Liu
QWQisheng Wang
Qisheng Wang
QSQinmei Sun
Qinmei Sun
ZLZhigang Lu
Zhigang Lu
Background: Zanthoxylum nitidum (Roxb.) DC., also named Liang Mianzhen (LMZ), one kind of Chinese herb characterized with anti-inflammatory and relieving pain potency, which is widely used to treat injuries, rheumatism, arthralgia, stomach pain and so on in China. But its mechanism related to the anti-hyperalgesic has not been reported. The aim of this study was to investigate the analgesic activity of Liang Mianzhen on mice with Complete Freund adjuvant (CFA)-induced chronic inflammatory pain. Meanwhile, the peripheral and central mechanisms of analgesic effect of Liang Mianzhen were further examined via observing the effects of Liang Mianzhen on the signal pathway associated with inflammatory induced hyperalgesia. Methods: The inflammatory pain model was established by intraplantar injection of CFA in C57BL/6J mice. After 1 day of CFA injection, the mice were treated with LMZ (100 mg/kg) for seven consecutive days, and the behavioral tests were measured after the daily intragastric administration of LMZ. The morphological changes on inflamed paw sections were determined by hematoxylin eosin (HE) staining. Changes in the mRNA expression levels of tumor necrosis factor (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) and nuclear factor κB p65 (NF-κBp65) were measured on day seven after CFA injection by using real-time quantitative PCR analysis and enzyme linked immunosorbent assay (ELISA) method, respectively. Moreover, immunohistochemistry and western blotting were used to detect extracellular regulated protein kinases 1/2 (ERK1/2) and NF-κB signal pathway activation. Results: The extract of LMZ (100 mg/kg) showed a significant anti-inflammatory and analgesic effect in the mice model. The paw edema volume was significantly reduced after the administration of LMZ compared to CFA group, as well as the paw tissues inflammatory damage was relived and the numbers of neutrophils in mice was reduced significantly. The CFA-induced mechanical threshold and thermal hyperalgesia value were significant improved with LMZ treatment at day three to day seven. We also found the mRNA levels of TNF-α, IL-1β, IL-6 and NF-κBp65 were down-regulate after 7 days from the LMZ treatment compared to CFA group. Meanwhile, LMZ significantly suppressed over-expression of the phosphorylation of ERK1/2 and NF-κBp65 in peripheral and central. Conclusion: The present study suggests that the extract of LMZ attenuates CFA-induced inflammatory pain by suppressing the ERK1/2 and NF-κB signaling pathway at both peripheral and central level.